October 25, 2021
Factor Bioscience Joins Strategic Partner Brooklyn ImmunoTherapeutics to Ring the Nasdaq Closing Bell
CAMBRIDGE, Mass., Oct. 25, 2021 — The executive leadership of Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies joined the leadership of Factor’s strategic partner, Brooklyn ImmunoTherapeutics (Nasdaq: BTX) today at the Nasdaq MarketSite in Times Square, New York, for the ringing of the Nasdaq closing bell by Brooklyn’s President and CEO, Howard J. Federoff, M.D., Ph.D. Factor Bioscience was represented by Co-Founder, Chairman, and CEO, Matt Angel, Ph.D., and Co-Founder and Chief Technology Officer, Christopher Rohde, Ph.D., while the Brooklyn team included Jay Sial, Chief Administrative Officer, Roger Sidhu, M.D., Chief Medical Officer, Ron Guido, M.S., M.S. Pharm. Med., Chief Development Officer, and Lynn Sadowski-Mason, M.S., EVP Clinical Operations.
Brooklyn ImmunoTherapeutics, a biopharmaceutical company focused on exploring the role of cytokine and gene editing/cell therapy in treating patients with cancer, blood disorders, and monogenic diseases, transferred its common stock listing from the NYSE American to the Nasdaq Global Market. The move was effective as of October 22, 2021. Its common stock began trading as a Nasdaq-listed security on October 25, 2021, and will continue to trade under the ticker symbol “BTX.”
“We were honored to be part of the occasion marking Brooklyn’s move to join the Nasdaq Global Market and we congratulate them.” said Dr. Angel. “We value our strong ties with Brooklyn and our close working relationship,” he added. Factor’s affiliate, Novellus Therapeutics Limited (“Novellus”), was acquired by Brooklyn ImmunoTherapeutics in July 2021. Novellus develops next‑generation engineered mesenchymal stem cell (“MSC”) therapies using extensively patented mRNA-based cell reprogramming and gene editing technologies licensed from Factor Bioscience. Brooklyn also has a license agreement with Factor, which grants Brooklyn exclusive rights to develop certain next-generation mRNA-based gene editing and cell therapy products.
About Factor Bioscience
Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience is privately held and is headquartered in Cambridge, MA. For more information, visit www.factorbio.com.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.
Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.
February 28, 2023
Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia
February 22, 2023
Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
January 4, 2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
May 16, 2022
Factor Bioscience to Deliver Four Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting